Business Context and Reporting Period
This Form 8-K, filed on November 4, 2025, reports on events occurring on November 2, 2025, involving CompoSecure, Inc. (NYSE: CMPO). The filing details the entry into a Material Definitive Agreement to acquire Husky Technologies Limited ("Husky") and the concurrent execution of a private placement of equity securities.
Key Financial Metrics and Transaction Terms
- Total Consideration for Husky Acquisition: Approximately $3.953 billion in cash and 55,297,297 shares of CompoSecure Class A Common Stock.
- Private Placement (PIPE): CompoSecure agreed to sell 106,056,083 shares of Common Stock at $18.50 per share, raising approximately $1.96 billion.
- Stock Issuance: The transaction involves the issuance of "Stock Consideration" shares to sellers and "PIPE Shares" to investors.
- Management Fees: Post-closing, an indirect subsidiary will pay quarterly management fees to Resolute Holdings Management, Inc.
Note: This filing does not provide historical revenue, profit, cash flow, or margin data for CompoSecure or Husky.
Material Changes and Agreements
The primary material change is the proposed combination of CompoSecure and Husky, which will result in Husky becoming an indirect wholly-owned subsidiary of CompoSecure. Key agreements executed include:
- Share Purchase Agreement: Defines the terms of the acquisition and closing conditions.
- Voting Agreement: Entities affiliated with Platinum Equity and others, holding approximately 41.3% of outstanding shares as of September 10, 2025, agreed to vote in favor of the stock issuance.
- Investor Rights Agreement: Grants Platinum Equity the right to nominate two board members while holding at least 10% of outstanding shares, and one member while holding between 5% and 10%.
- Lock-up Periods: Platinum Equity is subject to a 90-day lock-up; Resolute Compo Holdings LLC and affiliates are subject to a 365-day lock-up.
Conditions, Risks, and Outlook
Conditions to Closing: The transaction is subject to several conditions, including:
- Approval by a majority of CompoSecure stockholders.
- Receipt of regulatory clearances (merger control and foreign direct investment laws).
- Authorization for listing on the NYSE.
- Absence of material adverse effects on either party.
- Completion of pre-closing restructuring transactions.
Risks and Contingencies: The filing highlights risks regarding the failure to obtain required approvals, the potential for the transaction to be terminated if not closed within six months, and the possibility that expected benefits may not be realized. The transaction may also face litigation or regulatory actions.
Management Commentary: The CompoSecure Board has approved the transaction and recommends that stockholders vote in favor of the issuance of shares. The Board reserves the right to change its recommendation if an intervening event arises that would make a change consistent with fiduciary duties.
Investor Verification Checklist
- Verify the final approval status of the transaction by CompoSecure stockholders.
- Confirm the receipt of all necessary regulatory clearances and the absence of injunctions.
- Review the definitive proxy statement for detailed financial projections and risk factors.
- Monitor the closing of the $1.96 billion private placement as a condition precedent to the acquisition.
- Assess the impact of the 55.3 million new shares and 106 million PIPE shares on existing shareholder dilution.